Trials / Not Yet Recruiting
Not Yet RecruitingNCT04384601
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: A Phase 3 Multi-center Randomized Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 246 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
Detailed description
Non inferiority of SOX will be tested against FLOT. This study will be conducted at multiple center of China and will invite international centers to join it.The sponsor of this study is Ruijin Hospital and the project is supported by the Shanghai Key Laboratory of Gastric Neoplasms and Institute of Digestive Surgery, Shanghai.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chemotherapy | Perioperative chemotherapy will be administered according to description in two arms. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-09-01
- Completion
- 2027-09-01
- First posted
- 2020-05-12
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04384601. Inclusion in this directory is not an endorsement.